A Vorasidenib dose of 50 mg QD was selected and is under evaluation in the ongoing INDIGO study, randomized phase 3 in grade 2 non-enhancing IDH1/2 mutant glioma patients who have undergone surgery only (NCT04164901). Here, IDH1 is linked to central nervous system cancer.